Jean-Bernard Deloye

Title: Innovations of Jean-Bernard Deloye

Introduction

Jean-Bernard Deloye is a notable inventor based in Dijon, France. He has made significant contributions to the field of medical imaging, particularly in the development of radiolabeled compounds for cancer diagnosis.

Latest Patents

One of his key patents is the "Radiolabeled macrocyclic EGFR inhibitor." This invention relates to 18-Fluor radiolabeled macrocyclic quinazoline compounds, which are suitable as positron emission tomography (PET) tracers for imaging epidermal growth factor receptors (EGFR). The patent outlines their use in in vivo diagnosis, preclinical and clinical tumor imaging, patient stratification based on the mutational status of EGFR, and assessing tumor response to therapeutic treatments. The invention is particularly relevant to various cancers influenced by deregulated EGFR, including non-small cell lung cancer, pancreatic cancer, and breast cancer, among others.

Career Highlights

Jean-Bernard Deloye is associated with Oncodesign SA, a company focused on innovative solutions in the field of oncology. His work has contributed to advancements in cancer imaging and treatment strategies.

Collaborations

He has collaborated with notable colleagues such as Jan Marie Cyriel Jozef Hoflack and Cyril Berthet, enhancing the research and development efforts in his field.

Conclusion

Jean-Bernard Deloye's innovative work in the development of radiolabeled compounds has the potential to significantly impact cancer diagnosis and treatment. His contributions continue to advance the field of medical imaging and improve patient outcomes.